Cardiology

FDA announces new limits on high-dose simvastatin (Zocor)

The United States Food and Drug Administration (FDA) today announced new limitations to the use of high-dose simvastatin, due to the increased risk of muscle pain and weakness (myopathy) and in rare cases, kidney damage and ...

page 4 from 4